Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2016 (2016), Article ID 6293629, 2 pages
http://dx.doi.org/10.1155/2016/6293629
Editorial

PPAR in Cardiovascular Disorders

1Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Russian Academy of Sciences, Moscow 125315, Russia
2Institute for Atherosclerosis Research, Skolkovo Innovation Center, Moscow 121609, Russia
3Laboratory of Lipoproteins and Atherosclerosis, Baker Heart Research and Diabetes Institute, Melbourne, VIC 3004, Australia
4Department of Development and Regeneration, Katholieke Universiteit Leuven (KU Leuven), 3000 Leuven, Belgium
5Unit of Diabetes and Cardiovascular Prevention, School of Medicine, University of Palermo, 90127 Palermo, Italy

Received 14 June 2016; Accepted 14 June 2016

Copyright © 2016 Alexander N. Orekhov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, “Peroxisome proliferator-activated receptors: from genes to physiology,” Recent Progress in Hormone Research, vol. 56, pp. 239–263, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Boitier, J.-C. Gautier, and R. Roberts, “Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease,” Comparative Hepatology, vol. 2, article 3, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Robinson and D. J. Grieve, “Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease,” Pharmacology & Therapeutics, vol. 122, no. 3, pp. 246–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Shah, D. J. Rader, and J. S. Millar, “The effect of PPAR-α agonism on apolipoprotein metabolism in humans,” Atherosclerosis, vol. 210, no. 1, pp. 35–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. S. Millar, “Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk,” Current Opinion in Lipidology, vol. 24, no. 3, pp. 233–238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Vázquez-Carrera, “Unraveling the effects of PPARβ/δ on insulin resistance and cardiovascular disease,” Trends in Endocrinology & Metabolism, vol. 27, no. 5, pp. 319–334, 2016. View at Publisher · View at Google Scholar
  7. J. P. H. Wilding, “PPAR agonists for the treatment of cardiovascular disease in patients with diabetes,” Diabetes, Obesity and Metabolism, vol. 14, no. 11, pp. 973–982, 2012. View at Publisher · View at Google Scholar · View at Scopus